Pediatrik Onkolojide İlaç Ekstravazasyonu: Tek Merkez Deneyimi

Year 2008, Volume: 6 Issue: 2, 1 - 4, 01.09.2008

Betül Sevinir

Abstract

Amaç: Sitotoksik kemoterapi uygulamalarında ekstravazasyon sıklığı değişkendir. Bu çalışmanın amacı merkezimizde ekstravazasyon sıklığını ve risk faktörlerini tanımlamaktır.Gereç ve Yöntem: Uludağ Üniversitesi Tıp Fakültesi Pediatrik Onkoloji Bilim Dalı’nda 2004-2007 yılları arasındaki hasta kayıtları retrospektif olarak değerlendirildi. Tanı alan hasta sayısı, ekstravazasyon sayısı, demografik ve klinik özellikleribelirlendi.Bulgular: Merkezimizde pediatrik onkoloji hastalarında kemoterapi ekstravazasyonu insidansı %0.4 bulundu. Ekstravazasyon görülen hastaların %41’i üç yaşından küçüktü. Kemoterapi başlangıcından median 9 hafta sonra ekstravazasyon gözlendi.Ekstravazasyonların %77’si poliklinik koşullarında ve %59’u haftada bir tedavi alangrupta idi. En sık vinka alkaloidleri, aktinomisin ve adriamisin kaçışı saptandı.Sonuç: Sitotoksik kemoterapi ekstravazasyon sıklığı literatürle benzerdir. Dahaküçük çocuklarda ve daha sık kemoterapi alanlarda risk daha yüksektir

Keywords

Kemoterapi, ekstravazasyon, insidans, çocukluk çağı

Drug Extravasation in Pediatric Oncology: Single Center Experience

Abstract

Aim: The frequency of cytotoxic chemotherapy extravasation is uncertain. Theaim of this study was to determine extravasation frequency and to verify the riskfactors in our center.Materials and Methods: Hospital records of pediatric oncology patients at Uludağ University Faculty of Medicine, Department of Pediatric Oncology between2004-2007 were reviewed retrospectively. Number of the cases with chemotherapy extravasation, diagnosis, demographic and clinical features were recorded. Results: The incidence of cytotoxic drug extravasation in pediatric oncology cases was 0.4%. Forty-one percent of extravasations were observed in patientsunder 3 years The median extravasation time was 9th week of the chemotherapy. Most of the extravasation injuries were seen in outpatient clinic 77% andmainly in cases who were having therapy weekly 59% . The most frequent siteof extravasation was dorsal hand 82% . Causative drugs were vinca alkaloids,doxorubicin and dactinomycin.Conclusion: The incidence of chemotherapy induced extravasations were similarwith literature. Young age and weekly chemotherapy were major risk factors in pediatric oncology cases

Keywords

Chemotherapy, extravasation, incidence, childhood

References

• Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocuta- neous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367-98.
• Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006;7:45-63.
• Langstein HN, Duman H, Seeling D, et al. Retrospective study of the management of chemotherapy extravasation injury. Ann Plast Surg 2002;49:369-74.
• Ener RA, Meglathery SB, Styler M. Extravasation of syste- mic hemato-oncological therapies. Ann Oncol 2004;15:858-62.
• Hoşnuter M, Babucçu O, Kargı E, ve ark. Yaşlılarda sık görü- len bir medikal travma: “Ekstravazasyon yaralanmaları” sı- nıflama ve tedavi yaklaşımları. Türk Geriatri Dergisi 2005;8:101-6.
• Carr E, Jayabose S, Stringel G, et al. The safety of central li- ne placement prior to treatment of pediatric acute lymphob- lastic leukemia. Pediatr Blood&Cancer 2006;47:886-8.
• Demircioğlu F, Yılmaz S, Ören H, et al. Skin and soft tissue complications in pediatric leukemia patients with and wit- hout central venous catheters. J Pediatr Hematol Oncol 2008;30:32-5.
• Akyüz C, Yarış N, Şenocak ME, ve ark. Pediatrik Onkolojide tümüyle cilt altına yerleştirilen santral venöz kateterlerin kullanımı. Uluslararası Hematoloji Onkoloji Dergisi 2001;11:141-7.
• Schulmeister L. Managing vesicant extravasations. Oncolo- gist 2008;13:284-8.
• Alfaro-Rubio A, Sanmartin O, Requena C, et al. Extravasati- on of cytostatic agents: a serious complication of oncologi- cal treatment. Actas Dermosifiliogr 2006;97:169-76.
• Kumar RJ, Pegg SP, Kimble RM. Management of extravasa- tion injuries. ANZ J Surg 2001;71:285-9.
• Wang CL, Cohan RH, Ellis JH, et al. Frequency, manage- ment, and outcome of extravasation of nonionic iodinated contrast medium in 69 657 intravenous injections. Radiology 2007;243:80-7.
• Amaral JG, Traubici J, BenDavid G, et al. Safety of Power in- jector use in children as measured by incidence of extrava- sation. AJR 2006;187:580-3.
• Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant ex- travasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006;33:1134-41.
• Bozkurt AK, Uzel B, Akman C, et al. Intrathorasic extravasa- tion of antineoplastic agents: Case report and systematic review. Am J Clin Oncol 2003;26:121-3.